XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Description of Operations and Summary of Significant Accounting Policies (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Customer
Sep. 30, 2021
USD ($)
Jul. 20, 2022
Description of Operations and Summary of Significant Accounting Policies        
Decrease to accumulated deficit   $ 37,200    
Reduction to Additional Paid in Capital   65,400    
Purchases of equity investments managed by ISP Fund LP   (92,951) $ (178,445)  
Sales of equity investments managed by ISP Fund LP   24,281 21,426  
Purchase and sales of other investments managed by ISP Fund LP, net   (41,330) 267,019  
Increase in Deferred Tax Assets   $ 7,400    
Number of customers | Customer   3    
Theravance Respiratory Company, LLC        
Description of Operations and Summary of Significant Accounting Policies        
Equity method investment ownership percentage       15.00%
Customer Concentration Risk | Net Product Sales | La Jolla | Customer One        
Description of Operations and Summary of Significant Accounting Policies        
Concentration Risk, Percentage   32.00%    
Customer Concentration Risk | Net Product Sales | La Jolla | Customer Two        
Description of Operations and Summary of Significant Accounting Policies        
Concentration Risk, Percentage   32.00%    
Customer Concentration Risk | Net Product Sales | La Jolla | Customer Three        
Description of Operations and Summary of Significant Accounting Policies        
Concentration Risk, Percentage   29.00%    
Customer Concentration Risk | Receivables from Net Product Sales | La Jolla | Customer One        
Description of Operations and Summary of Significant Accounting Policies        
Concentration Risk, Percentage   34.00%    
Customer Concentration Risk | Receivables from Net Product Sales | La Jolla | Customer Two        
Description of Operations and Summary of Significant Accounting Policies        
Concentration Risk, Percentage   23.00%    
Customer Concentration Risk | Receivables from Net Product Sales | La Jolla | Customer Three        
Description of Operations and Summary of Significant Accounting Policies        
Concentration Risk, Percentage   35.00%    
Prior Period Immaterial Correction        
Description of Operations and Summary of Significant Accounting Policies        
Purchases of equity investments managed by ISP Fund LP $ (178,400)   (178,400)  
Sales of equity investments managed by ISP Fund LP 21,400   21,400  
Purchase and sales of other investments managed by ISP Fund LP, net $ 267,000   $ 267,000  
2025 Notes        
Description of Operations and Summary of Significant Accounting Policies        
Increase in convertible notes   $ 35,600    
Minimum | Customer Concentration Risk | Net Product Sales        
Description of Operations and Summary of Significant Accounting Policies        
Concentration Risk, Percentage   10.00%    
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | RELVAR/BREO        
Description of Operations and Summary of Significant Accounting Policies        
Royalty rate for first level of annual global net sales (as a percent)   15.00%    
Annual global sales level used to determine royalty rate   $ 3,000,000    
Royalty rate for sales above first level of annual global net sales (as a percent)   5.00%    
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Minimum        
Description of Operations and Summary of Significant Accounting Policies        
Royalty rate for combination products (as a percent)   6.50%    
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Maximum        
Description of Operations and Summary of Significant Accounting Policies        
Royalty rate for combination products (as a percent)   10.00%